The therapeutic community is excited with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s demonstrating significant potential in clinical trials for treating obesity. Unlike some existing weight loss treatments, retatrutide appears to provide a significant substantial decrease in body size and benefit metaboli